OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Lykke Hinsch Gylvin։ Boehringer Ingelheim and Microsoft Explore AI and Digital Twins to Accelerate Clinical Research

Why Women Still Face Barriers at the Top of Medical Research? - CancerWorld

Methotrexate for Osteosarcoma: Uses, Benefits and Side Effects

Marzia Zambon Highlights Europa Donna's Participation at ESMO 2026

What’s New On Radiotherapy of Prostate Cancer in 2026?

Oncology News, Insights, Stories by OncoDaily

Election
Career Updates

ASCO Election 2026: Meet the 11 Candidates for Leadership Positions

AbbVie Submits Etentamig BLA to FDA for Relapsed/Refractory Multiple Myeloma
Hematology

AbbVie Submits Etentamig BLA to FDA for Relapsed/Refractory Multiple Myeloma

PHERGain
Breast Oncology

PHERGain Five-Year Results: Chemotherapy-Free HER2-Positive Breast Cancer Treatment Shows Durable Outcomes as ctDNA Refines Risk Assessment

Adult ALL Treatment in 2026: Promising Advances and Remaining Challenges

KEYNOTE-867 Phase III: Pembrolizumab Plus SBRT Fails to Improve Event-Free Survival and Increases Severe Toxicity in Early-Stage NSCLC

Deb Schrag: Reflecting on an Inspiring ESMO 2026 and Its Bold Scientific Discussions

Gilberto Lopes: Affordable, Timely Cancer Care Without Financial Ruin

Dario Trapani: Rethinking How We Measure Benefit in Cancer Care

Richard Sullivan: The Growing Crisis of Cancer Drug Pricing and Affordability

ISASOCUT: Subcutaneous Isatuximab With On-Body Injector in Newly Diagnosed Multiple Myeloma

Voices
Ibtihal Fadhil

Ibtihal Fadhil: Opportunity to Join a Discussion on Cancer Care in the Eastern Mediterranean at London Global Cancer Week 2026

Shafin Kalyan: Veridata Health Joins the October 2026 Cohort of Mayo Clinic Platform Accelerate

Tanja Obradovic։ Few More Days to Register for Free Webinar "The Role of APAC in Global Oncology Development"

Peter MacCallum Cancer Centre Highlights Its Experts’ Contributions at ESMO 2026

Abdulaziz AlJassim: Great Memories and Inspiring Scientific Discussions at ESMO 2026

ESHO Congratulates Fellows on Completing Hemato-Oncology Fellowship Training

John Christodouleas: My Top 3 'Most Exciting' Clinical Observations from Day 1 of the MR-Linac Consortium

FDA Approvals
CLL/SLL Pirtobrutinib

FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Niklas Klümper: FDA Approves Belzutifan Plus Lenvatinib in Advanced ccRCC

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Floretyrosine F 18 for PET Imaging in Glioma

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

Celebrities and Cancer

OncoCalendar

ESO Ambassador Event on Neoadjuvant and Post-Neoadjuvant Treatment in Breast Cancer

European School of Oncology (ESO) College

30 Oct
Breast Cancer

2026 Advances in Chronic Graft-Versus-Host Disease

Memorial Sloan Kettering Cancer Center (MSK)

30 Oct
Graft-Versus-Host Disease

London Global Cancer Week - LGCW 2026

London Global Cancer Week

02 Nov
Global Cancer Week

Rare Gynecologic Cancers: Advancing Knowledge through Collaboration in Research and Clinical Care

The University of Texas MD Anderson Cancer Center

02 Nov
Rare Gynecologic Cancers

L’Oncodaily Session During London Cancer Week 2026

London Global Cancer Week

02 Nov
L’Oncodaily Session

Chromosomes in Crisis: From Chromosomal Instability to Catastrophes in Cancer Genomes

European Association for Cancer Research

03 Nov
Chromosomes in Crisis

GPON 2026 – Empowered Oncology Nurses Transform Cancer Care

Global Power of Oncology Nursing (GPON)

03 Nov
GPON 2026

SITC 2026

Society for Immunotherapy of Cancer

04 Nov
SITC

The ACCC Oncology Reimbursement Meeting – Reno

Association of Cancer Care Centers (ACCC)

04 Nov
ACCC Oncology

EORTC Genito-Urinary Cancer Group Autumn Meeting 2026

04 Nov
Genito-Urinary Cancer

Cancer Research UK Lung Cancer Centre of Excellence – Conference 2026

Cancer Research UK

04 Nov
Cancer Research UK

International Symposium of Critical Care in Cancer Patients

MD Anderson Cancer Center

04 Nov
International Symposium of Critical Care

Immune-oncology
ESMO 2026: The Key Pembrolizumab Trials to Know

ESMO 2026: The Key Pembrolizumab Trials to Know

ESMO 2026: What’s New in Melanoma Immunotherapy?

KEYNOTE-C93 Trial: Pembrolizumab Versus Chemotherapy in dMMR Endometrial Cancer

MOIO Trial: Can Immunotherapy Be Given Less Frequently?

KN035-CN-005 Trial: Envafolimab Plus GEMOX in Advanced Biliary Tract Cancer

PEARLS/KEYNOTE-091: Long-Term Outcomes With Adjuvant Pembrolizumab in NSCLC

DeLLphi-304 Trial: Tarlatamab Versus Chemotherapy in SCLC

Gastrointestinal-Oncology
PRABITAS

Phase III PRABITAS Trial: 14-Day vs 28-Day Lonsurf Plus Bevacizumab for Refractory mCRC

Key Updates in GI Oncology From ESMO 2026

NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer

OPTIMUM at ESMO 2026: Maintenance Olaparib With or Without Durvalumab in DDR-Mutated Advanced Biliary Tract Cancer

LEAP-012 at ESMO 2026: Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC

C-CAR031 at ESMO 2026 : Updated Results of GPC3-Targeted Armored CAR-T Therapy in Advanced HCC

Phase II HRS-4642 Plus Chemotherapy With or Without Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results at ESMO 2026

Breast-Oncology
Triple-negative breast cancer in Algeria

Triple-Negative Breast Cancer in Algeria in 2026: What Has Changed?

PHERGain Five-Year Results: Chemotherapy-Free HER2-Positive Breast Cancer Treatment Shows Durable Outcomes as ctDNA Refines Risk Assessment

HER2-Low Breast Cancer in Algeria: When a Low HER2 Signal Becomes Clinically Relevant

What Changes in Breast Oncology After ESMO 2026? The Trials, Treatment Shifts, and Unanswered Questions Shaping Clinical Practice

OptiTROP-Breast01 Final Analysis: Sacituzumab Tirumotecan Sustains Overall Survival Benefit in Previously Treated Metastatic Triple-Negative Breast Cancer

HR-Positive, HER2-Negative Breast Cancer in Algeria: Beyond Endocrine Therapy Alone

HER2-Positive Breast Cancer in Algeria: What Happens After Neoadjuvant Therapy?

Lung-Oncology
KEYNOTE-867

KEYNOTE-867 Phase III: Pembrolizumab Plus SBRT Fails to Improve Event-Free Survival and Increases Severe Toxicity in Early-Stage NSCLC

What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment

ASTRIDE: Serplulimab Shows Numerically Longer Overall Survival Than Atezolizumab in US Patients With Extensive-Stage Small Cell Lung Cancer

SANOVO Phase III: Savolitinib Plus Osimertinib Significantly Prolongs First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC, With Strong Overall Survival Signal

MDT-BRIDGE: Early ctDNA Clearance Predicts Pathological Response and Favorable Outcomes in Stage II–III NSCLC

PEARLS/KEYNOTE-091 Final Analysis: Pembrolizumab Maintains Disease-Free Survival Benefit but Does Not Improve Overall Survival After Seven Years

Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

OncoDaily TV
Dr Gevorg Tamamyan

Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg Tamamyan’s WHO DG Campaign

Rachel Purcell

Rachel Purcell Highlights New Zealand’s Nationwide Exercise Program for Bowel Cancer Patients

Alicia Fong

Alicia Fong: Exploring the Role of AI in Cancer Detection and Treatment

Dr Gevorg Tamamyan

“Stronger Regions, Stronger Countries…” – Dr Gevorg Tamamyan

Rejin Kebudi

“Diligent, Intelligent, Capable of Reaching Many Colleagues Globally ” – Rejin Kebudi, General Secretary of the International Society of Pediatric Oncology, about Dr Gevorg Tamamyan Upon His WHO DG Candidacy

Dr. Gevorg Tamamyan

“One of the Most Amazing and Truly Legendary Oncologists of Our Time” – Dr. Gevorg Tamamyan on Dr. Julie Gralow, Chief Medical Officer of ASCO

Dr Gevorg Tamamyan

“I Still Remember His Mentees That Spoke So Highly of Him… Having a Vision Means Investing in People That Will Make a Difference For the Years to Come” – Albanian Hematologist Liri Seraj Supports Dr Gevorg Tamamyan as WHO DG Candidate

World Radiotherapy Awareness Day

12 Countries, One Vision for the Future of Radiotherapy – World Radiotherapy Awareness Day

Bishal Gyawali

Erika Ruiz-Garcia Joins Bishal Gyawali on Grounded In Groundshot Podcast

Dr Gevorg Tamamyan

“One Planet is Not Enough For His Vision” – Dr Amalya Sargsyan Celebrates Her Mentor Dr Gevorg Tamamyan

Dr Gevorg Tamamyan

Renowned Surgeon and Inventor of Abraxane, Philanthropist Dr Patrick Soon-Shiong Endorses Dr Gevorg Tamamyan as WHO Director-General Candidate

Burnout

Oncology Beyond Guidelines: Burnout, Imposter Syndrome, Mentorship & Cancer Prevention with Imène Hadji

Not To Miss
AbbVie Submits Etentamig BLA to FDA for Relapsed/Refractory Multiple Myeloma

AbbVie Submits Etentamig BLA to FDA for Relapsed/Refractory Multiple Myeloma

25 Posts Not to Miss from ESMO Congress 2026: Day 5

25 Posts Not to Miss from ESMO Congress 2026: Day 4

25 Posts Not to Miss from ESMO Congress 2026: Day 3

20 Posts Not to Miss from ESMO Congress 2026: Day 2

20 Posts Not to Miss from ESMO Congress 2026: Day 1

UICC Announces New Board of Directors for 2026–2028

OncoGrants
Exploration Call

KWF Dutch Cancer Society — Exploration Call 2027

Childhood Eye Cancer

Childhood Eye Cancer Trust Research Grants 2026–2027

Emerging Technologies

NCI Advanced Development and Validation of Emerging Technologies for Cancer Research 2026

Florida Breast Cancer Foundation

Florida Breast Cancer Foundation Direct Services Grants 2027

CDMRP

CDMRP Breast Cancer Clinical Research Extension Award 2026

Chordoma Foundation

CRI–Chordoma Foundation Impact Grant 2027

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions

CancerWorld

Oncologists
Nazik Hammad

Nazik Hammad

Oncologists Location Toronto, Canada
Sarah Tasian

Sarah Tasian

Oncologists Location Philadelphia, USA
Trinanjan Basu

Trinanjan Basu

Oncologists Location Mumbai, India
Darya Kizub

Darya Kizub

Oncologists Location Houston, USA
Iyad Sultan

Iyad Sultan

Oncologists Location Amman, Jordan
Yisihak Suga Debodina

Yisihak Suga Debodina

Oncologists Location Addis Ababa, Ethiopia
Miriam Mutebi

Miriam Mutebi

Oncologists Location Nairobi, Kenya
Yasmine Yasser Hassaneen

Yasmine Yasser Hassaneen

Oncologists Location Cairo, Egypt

Drugs Atlas
Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers Adagrasib (Krazati; MRTX849) Oct 30, 2026 12:57 am
Infigratinib (Truseltiq; BGJ398): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR2-Rearranged Cholangiocarcinoma Infigratinib (Truseltiq; BGJ398) Oct 30, 2026 12:56 am
Futibatinib (Lytgobi): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma Futibatinib (Lytgobi) Oct 28, 2026 1:27 pm
Pemigatinib (Pemazyre): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR-Driven Cancers and Myeloid/Lymphoid Neoplasms Pemigatinib (Pemazyre) Oct 28, 2026 1:02 am
Quizartinib (Vanflyta): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FLT3-ITD–Positive Acute Myeloid Leukemia Quizartinib (Vanflyta) Oct 26, 2026 2:27 am
Gilteritinib (Xospata): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Relapsed or Refractory FLT3-Mutated AML Gilteritinib (Xospata) Oct 26, 2026 1:34 am
Ruxolitinib (Jakafi): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease Ruxolitinib (Jakafi) Oct 24, 2026 1:00 pm
Midostaurin (Rydapt): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FLT3-Mutated AML and Advanced Systemic Mastocytosis Midostaurin (Rydapt) Oct 24, 2026 12:58 pm
Fedratinib (Inrebic): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Myelofibrosis Fedratinib (Inrebic) Oct 23, 2026 2:28 am
Ponatinib (Iclusig): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in CML and Philadelphia Chromosome-Positive ALL Ponatinib (Iclusig) Oct 23, 2026 2:03 am

OncoDaily Magazine

New Paper Alert
Stephen Liu

Stephen Liu Shares the New Report on Zongertinib's Clinical Usage in Patients with HER2 Mutated NSCLC

Catarina Simões Padilla, Olga Husson, Winette van der Graaf

Congratulations to Catarina Simões Padilla, Olga Husson, Winette van der Graaf on QoL Research - EORTC

Allan Pereira

Allan Pereira: MASTERPLAN Shows SBRT More Than Halves Locoregional Recurrence in Pancreatic Cancer

Nicholas Hornstein

Nicholas Hornstein: IROCAS Trial Finds No DFS Benefit From Adjuvant Irinotecan in High-Risk Colon Cancer

Jon Wigginton

Jon Wigginton: New Survival Data for Tarlatamab Plus Durvalumab Presented at ESMO 2026

Brian Slomovitz

Brian Slomovitz to Present KEYNOTE-C93 Phase 3 Results at ESMO 2026

OncoDaily Medical Journal

GU Oncology

10.69690/ODMJ-001-1026-8269

Psychosocial burden and lifestyle impact in patients with renal cell carcinoma: a patient-reported outcomes analysis
Original Research

Pediatric Oncology

10.69690/ODMJ-001-1026-8309

Limited Prognostic Value of Baseline Curie Score in Children with High-Risk Neuroblastoma Treated with Contemporary Multi-modal Therapy: A Single-Center Retrospective Cohort Study
Original Research

Breast Cancer

10.69690/ODMJ-001-1026-8231

Variable-Volume Oncoplastic Reconstruction Using a Modified Würinger Central Pedicle Technique for Upper Quadrants Breast Cancer: a single-center experience
Original Research

GI Oncology

10.69690/ODMJ-001-1026-8138

Association of Alpha-Fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Camrelizumab Plus Rivoceranib vs Sorafenib: Post Hoc Exploratory Analysis of the CARES-310 Trial
Original Research

Oncology Nursing

10.69690/ODMJ-002-0926-8087

Risk of Atrial Fibrillation in Breast Cancer Patients Treated with Radiotherapy: A Scoping Review
Reviews

Pediatric Oncology

10.69690/ODMJ-011-0826-7849

Integrated Management of Endo and Exo-pelvic Sacrococcygeal Teratomas (Altman type III): Report of Two Cases
Case Reports & Case Series

Oncology Nursing

10.69690/ODMJ-001-0826-7778

Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Original Research

Oncology Nursing

10.69690/ODMJ-002-0826-7795

Late presentation in cancer care: Implications for treatment and survival: A Narrative Review
Reviews